Oct 2026· Critical reviews in oncology/hematology· pp.
105652
· 0 citations· 60 references
Medicine
Abstract
Background
The prognostic value of circulating tumor DNA (ctDNA) remains controversial. This meta-analysis systematically evaluates the association between ctDNA status and prognosis in esophageal cancer (EC) and gastric cancer (GC) (including gastroesophageal junction cancer), stratified by resectability and treatment stage.
Methods
PubMed, Web of Science, EMBASE and Scopus were systematically searched up to February 2026. Pooled hazard ratios (HRs) and 95% confidence intervals (95%CIs) were used to quantify disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS).
Results
Forty-four studies were included: 28 on resectable cancer, 17 on unresectable cancer (among which one study covered both types). In resectable cancer, ctDNA positivity was associated with worse DFS at baseline (HR=2.45, 95%CI: 1.18-5.07), after neoadjuvant therapy (HR=3.89, 95%CI: 2.50-6.06), after radical surgery (HR=6.76, 95%CI: 4.72-9.67), and follow-up (HR=19.17, 95%CI: 12.69-28.96). ctDNA positivity was also associated with worse OS at baseline (HR=1.89, 95%CI: 1.13-3.16), after neoadjuvant therapy (HR=3.40, 95%CI: 2.03-5.69), and after radical surgery (HR=4.52, 95%CI: 2.70-7.58). In resectable cancer, ctDNA positivity was associated with both DFS and OS, and the association differed between treatment time points (DFS: Q-test P<0.001; OS: Q-test P=0.05). In unresectable cancer, baseline ctDNA positivity was associated with worse PFS (HR=2.17, 95%CI: 1.31-3.60) and OS (HR=2.04, 95%CI: 1.54-2.70). During treatment, ctDNA positivity was associated with worse PFS (HR=2.72, 95%CI: 1.63-4.52) and OS (HR=2.63, 95%CI: 1.52-4.55).
Conclusion
ctDNA positivity was associated with worse prognosis in both resectable and unresectable EC and GC. In resectable cancer, the association with DFS and OS differed between treatment time points.
The meta-analysis revealed a significant correlation between positive ctDNA status and worse survival outcomes, including DFS/RFS, and ctDNA consistently predicted worse survival outcomes for patients with rectal cancer.
Tao Jin, Er-Shuo Du, Xiao-Rui Fu et al.· BMC Cancer· 0 citations
The value of circulating tumour DNA (ctDNA) in resectable colorectal cancer (CRC) remains unclear. The present study evaluated the efficacy of ctDNA-guided adjuvant chemotherapy (ACT) in patients with resectable CRC after surgery. A systematic search was conducted in PubMed, Web of Science, EMBASE and the Cochrane Libr...
Jia-Le Ruan, Wen Shi, Wen Shi et al.· Oncology Letters· 0 citations
Summary Background Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies, with limited survival benefits despite recent therapeutic advances. Few prognostic biomarkers are available for PDAC monitoring in clinical practice. We conducted a meta-analysis to evaluate and synthesise evidence on the...
L. Ulmann, M. Obeidat, S. Bunduc et al.· EBioMedicine· 0 citations
BACKGROUND
Recurrence after curative-intent treatment remains common in HCC. Circulating tumor DNA (ctDNA) may provide prognostic information, but evidence is heterogeneous.
METHODS
We reviewed 12 cohort studies (880 patients) with HCC treated with curative intent. Associations of preoperative or postoperative ctDNA...
Salah A. Abdelrahim, Reem M. Gahtani, Sameer Alqassimi et al.· Surgical oncology· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, and reliable prognostic biomarkers are urgently needed to guide risk stratification and treatment. CD74 has been implicated in tumor progression, invasion, and pro-inflammatory signaling in various cancers. This systematic review...
I. Vacariu, S. Ilie, C. Vere et al.· International Journal of Mol...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.